Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Blinding

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Randomized Experiments

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials.

Molecular cancer therapeutics·2025

Same author

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials.

Molecular cancer therapeutics·2025

Same author

Analysis of the Political Viewpoint of Policy Statements From Professional Medical Organizations Using ChatGPT With GPT-4: Cross-Sectional Study.

JMIR formative research·2025

Same author

Reply to 'Surrogate end points in oncology: aligning drug development incentives and patient needs'.

Nature reviews. Clinical oncology·2025

Same author

Characterization of bridging therapies in clinical trials leading to FDA approval of CAR-T cell therapies.

International journal of cancer·2025

Same author

Surrogate end points in oncology: the speed-uncertainty trade-off from the patients' perspective.

Nature reviews. Clinical oncology·2025

Search research articles

Related Experiment Video

Updated: Sep 4, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Common misconceptions of randomized controlled trials in oncology.

Kerrington Powell¹, Vinay Prasad²

¹College of Medicine, Texas A&M Health Science Center, Bryan, Texas, USA.

European Journal of Clinical Investigation

|July 17, 2022

Summary

Randomized controlled trials (RCTs) are crucial in biomedicine but face misconceptions in oncology. This study clarifies these issues and proposes solutions to improve RCT methodology and implementation for better healthcare.

Keywords:

oncology randomized controlled trial study design

More Related Videos

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Sep 4, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

Biomedical research
Clinical trials
Oncology

Background:

Randomized controlled trials (RCTs) are the gold standard in evidence-based medicine.
Properly designed RCTs inform drug regulation and clinical guidelines.
Misconceptions about RCTs persist, especially in oncology.

Purpose of the Study:

To address common misconceptions regarding randomized controlled trials in oncology.
To propose solutions for enhancing RCT methodology and implementation.
To improve the value-based healthcare landscape in oncology.

Main Methods:

Literature review and expert consensus on RCTs in oncology.
Analysis of common misconceptions including design, duration, cost, appraisal, industry influence, and ethics.
Development of strategic frameworks for improving RCTs.

Main Results:

Identified key misconceptions hindering RCTs in oncology.
Outlined strategies to overcome challenges in RCT design and execution.
Highlighted the potential of regulatory and strategic frameworks to enhance RCTs.

Conclusions:

Addressing misconceptions can improve the quality and efficiency of oncology RCTs.
Enhanced RCTs contribute to evidence-based drug regulation and national guidelines.
Improving RCTs maximizes value-based healthcare and reduces unethical trial duplication.